Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.
复制标题
DOI：
10.1038/sj.bjc.6604977
复制
发表时间：
2009-04-21
影响因子：
8.8
通讯作者：
Mueller, B. U.
中科院分区：
文献类型：
--
作者：
Pabst, T.;Eyholzer, M.;Fos, J.;Mueller, B. U.
AML中的CCAAT/增强子结合蛋白α（CEBPA）突变与良好的预后相关，并分为N端和C端突变。大多数AML患者都有这两种类型的突变。我们评估了224例AML患者中CEBPA单突变（n=7）和双突变（n=12）的预后意义。双CEBPA突变赋予了决定性的有利的总体（P=0.006）和无病生存（P=0.013）。然而，单CEBPA突变患者的临床结果与CEBPA野生型患者没有差异。在多变量分析中，只有双CEBPA突变而不是单CEBPA突变被确定为独立的预后因素。这些发现表明CEBPA突变AML患者的异质性。
CCAAT/enhancer binding protein alpha (CEBPA) mutations in AML are associated with favourable prognosis and are divided into N- and C-terminal mutations. The majority of AML patients have both types of mutations. We assessed the prognostic significance of single (n=7) and double (n=12) CEBPA mutations among 224 AML patients. Double CEBPA mutations conferred a decisively favourable overall (P=0.006) and disease-free survival (P=0.013). However, clinical outcome of patients with single CEBPA mutations was not different from CEBPA wild-type patients. In a multivariable analysis, only double – but not single – CEBPA mutations were identified as independent prognostic factors. These findings indicate heterogeneity within AML patients with CEBPA mutations.
登录
查看更多内容
影响因子：
5.3
作者：
Radomska, HS;Huettner, CS;Tenen, DG
通讯作者：
Tenen, DG
DOI：
10.1073/pnas.0404731101
发表时间：
2004-09-07
影响因子：
11.1
作者：
Helbling, D;Mueller, BU;Pabst, T
通讯作者：
Pabst, T
影响因子：
45.3
作者：
Marcucci, Guido;Maharry, Kati;Bloomfield, Clara D.
通讯作者：
Bloomfield, Clara D.
影响因子：
45.3
作者：
Fröhling, S;Schlenk, RE;Döhner, K
通讯作者：
Döhner, K
影响因子：
15.3
作者：
Radomska, HS;Bassères, DS;Zheng, R;Zhang, P;Dayaram, T;Yamamoto, Y;Sternberg, DW;Lokker, N;Giese, NA;Bohlander, SK;Schnittger, S;Delmotte, MH;Davis, RJ;Small, D;Hiddemann, W;Gilliland, DG;Tenen, DG
通讯作者：
Tenen, DG